Pfizer receives request from FDA for more information on application for lasofoxifene
PFE | Quote | Chart | News | PowerRating -- Pfizer Inc (NYSE:PFE), a pharmaceutical company, announced on 16
January that it has received a complete response letter from the US
Food and Drug Administration (FDA) requesting additional information of
the company's application for lasofoxifene.
The company stated that it is reviewing the letter and will cooperate
with the FDA to determine the next step in its application.
The current application for lasofoxifene was submitted by Pfizer on 18
December 2007. An FDA scientific advisory panel voted 9 to 3 that there
is a population of post-menopausal women with osteoporosis for whom the
benefits of lasofoxifene would likely outweigh the risks. The FDA is
not required to follow the panel's advice.
Lasofoxifene is a selective oestrogen receptor modulator (SERM),
currently under review for the treatment of osteoporosis in
post-menopausal women with an increased risk of fracture.
Comments on this story may be sent to admin@m2.com
For full details on Pfizer Inc (PFE) PFE. Pfizer Inc (PFE) has Short Term PowerRatings at TradingMarkets. Details on Pfizer Inc (PFE) Short Term PowerRatings is available at This Link.
- Pfizer teams up to offer online health management - 02/09/10
- Atrium's role at Pfizer growing - 02/09/10
- BRIEF: Pfizer partners with interactive-technology firm to help boost health outcomes - 02/08/10
- Pfizer and Keas Partner to Help Consumers Take a More Active Role in Their Health and Wellness - 02/08/10
- BRIEF: Bristol-Myers freezing salaries - 02/06/10
- More News >>


